Rexahn licenses pancreatic cancer drug candidate in China 18-Apr-2019 By Maggie Lynch The $226m licensing agreement sees the development and commercialization of a targeted treatment for pancreatic and hard to treat cancers in China.
Q&A Rexahn combines small and large molecules with Keytruda collab 22-Oct-2018 By Flora Southey Rexahn Pharmaceuticals will combine its small molecule compound RX-5902 with Merck’s anti-PD-therapy, Keytruda, to evaluate its efficacy in patients with metastatic triple negative breast cancer.